Effects of peritumoral bevacizumab injection against oral squamous cell carcinoma in a nude mouse xenograft model

A preliminary study

Hisato Yoshida, Hitoshi Yoshimura, Shinpei Matsuda, Takashi Ryoke, Tamotsu Kiyoshima, Motohiro Kobayashi, Kazuo Sano

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Angiogenesis serves a crucial role in tumor growth. Vascular endothelial growth factor (VEGF) is a potent regulator of tumor angiogenesis and is highly expressed in oral squamous cell carcinoma (OSCC). Bevacizumab, which binds to VEGF-A, inhibits the biological activity of VEGF and is clinically administered by intravenous injection. As intravenous chemotherapy intensifies the side effects experienced by OSCC patients, an alternative treatment option is desirable, particularly for older patients with OSCC who present with systemic disease complications. Generally, local injections of antitumor agents enhance tumoricidal activity and decrease side effects. However, the antitumor effects of peritumoral bevacizumab injections in OSCC are not fully understood. Therefore, the present study examined the effects of peritumoral bevacizumab injections in an experimental nude mouse model of OSCC through immunohistochemical staining for cluster of differentiation (CD)31 and α-smooth muscle actin (α‑SMA) and apoptosis assays. It was identified that peritumoral injections of bevacizumab significantly inhibited tumor growth in OSCC xenografts compared with peritumoral saline injections or no treatment (controls), and it was also revealed that treatment with bevacizumab significantly reduced CD31- and α-SMA-positive microvessel density (P<0.01) and increased level of tumor cell apoptosis (P<0.01) compared with the controls. In conclusion, these results collectively support the experimental basis for the clinical development of peritumoral bevacizumab injections for the treatment of OSCC.

Original languageEnglish
Pages (from-to)8627-8634
Number of pages8
JournalOncology Letters
Volume15
Issue number6
DOIs
Publication statusPublished - Jun 1 2018

Fingerprint

Heterografts
Nude Mice
Squamous Cell Carcinoma
Injections
Vascular Endothelial Growth Factor A
Smooth Muscle
Actins
Neoplasms
Apoptosis
Therapeutics
Growth
Microvessels
Bevacizumab
Intravenous Injections
Antineoplastic Agents
Staining and Labeling
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Effects of peritumoral bevacizumab injection against oral squamous cell carcinoma in a nude mouse xenograft model : A preliminary study. / Yoshida, Hisato; Yoshimura, Hitoshi; Matsuda, Shinpei; Ryoke, Takashi; Kiyoshima, Tamotsu; Kobayashi, Motohiro; Sano, Kazuo.

In: Oncology Letters, Vol. 15, No. 6, 01.06.2018, p. 8627-8634.

Research output: Contribution to journalArticle

Yoshida, Hisato ; Yoshimura, Hitoshi ; Matsuda, Shinpei ; Ryoke, Takashi ; Kiyoshima, Tamotsu ; Kobayashi, Motohiro ; Sano, Kazuo. / Effects of peritumoral bevacizumab injection against oral squamous cell carcinoma in a nude mouse xenograft model : A preliminary study. In: Oncology Letters. 2018 ; Vol. 15, No. 6. pp. 8627-8634.
@article{af8f252ed8054f01948a1d352a8f9d26,
title = "Effects of peritumoral bevacizumab injection against oral squamous cell carcinoma in a nude mouse xenograft model: A preliminary study",
abstract = "Angiogenesis serves a crucial role in tumor growth. Vascular endothelial growth factor (VEGF) is a potent regulator of tumor angiogenesis and is highly expressed in oral squamous cell carcinoma (OSCC). Bevacizumab, which binds to VEGF-A, inhibits the biological activity of VEGF and is clinically administered by intravenous injection. As intravenous chemotherapy intensifies the side effects experienced by OSCC patients, an alternative treatment option is desirable, particularly for older patients with OSCC who present with systemic disease complications. Generally, local injections of antitumor agents enhance tumoricidal activity and decrease side effects. However, the antitumor effects of peritumoral bevacizumab injections in OSCC are not fully understood. Therefore, the present study examined the effects of peritumoral bevacizumab injections in an experimental nude mouse model of OSCC through immunohistochemical staining for cluster of differentiation (CD)31 and α-smooth muscle actin (α‑SMA) and apoptosis assays. It was identified that peritumoral injections of bevacizumab significantly inhibited tumor growth in OSCC xenografts compared with peritumoral saline injections or no treatment (controls), and it was also revealed that treatment with bevacizumab significantly reduced CD31- and α-SMA-positive microvessel density (P<0.01) and increased level of tumor cell apoptosis (P<0.01) compared with the controls. In conclusion, these results collectively support the experimental basis for the clinical development of peritumoral bevacizumab injections for the treatment of OSCC.",
author = "Hisato Yoshida and Hitoshi Yoshimura and Shinpei Matsuda and Takashi Ryoke and Tamotsu Kiyoshima and Motohiro Kobayashi and Kazuo Sano",
year = "2018",
month = "6",
day = "1",
doi = "10.3892/ol.2018.8399",
language = "English",
volume = "15",
pages = "8627--8634",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - Effects of peritumoral bevacizumab injection against oral squamous cell carcinoma in a nude mouse xenograft model

T2 - A preliminary study

AU - Yoshida, Hisato

AU - Yoshimura, Hitoshi

AU - Matsuda, Shinpei

AU - Ryoke, Takashi

AU - Kiyoshima, Tamotsu

AU - Kobayashi, Motohiro

AU - Sano, Kazuo

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Angiogenesis serves a crucial role in tumor growth. Vascular endothelial growth factor (VEGF) is a potent regulator of tumor angiogenesis and is highly expressed in oral squamous cell carcinoma (OSCC). Bevacizumab, which binds to VEGF-A, inhibits the biological activity of VEGF and is clinically administered by intravenous injection. As intravenous chemotherapy intensifies the side effects experienced by OSCC patients, an alternative treatment option is desirable, particularly for older patients with OSCC who present with systemic disease complications. Generally, local injections of antitumor agents enhance tumoricidal activity and decrease side effects. However, the antitumor effects of peritumoral bevacizumab injections in OSCC are not fully understood. Therefore, the present study examined the effects of peritumoral bevacizumab injections in an experimental nude mouse model of OSCC through immunohistochemical staining for cluster of differentiation (CD)31 and α-smooth muscle actin (α‑SMA) and apoptosis assays. It was identified that peritumoral injections of bevacizumab significantly inhibited tumor growth in OSCC xenografts compared with peritumoral saline injections or no treatment (controls), and it was also revealed that treatment with bevacizumab significantly reduced CD31- and α-SMA-positive microvessel density (P<0.01) and increased level of tumor cell apoptosis (P<0.01) compared with the controls. In conclusion, these results collectively support the experimental basis for the clinical development of peritumoral bevacizumab injections for the treatment of OSCC.

AB - Angiogenesis serves a crucial role in tumor growth. Vascular endothelial growth factor (VEGF) is a potent regulator of tumor angiogenesis and is highly expressed in oral squamous cell carcinoma (OSCC). Bevacizumab, which binds to VEGF-A, inhibits the biological activity of VEGF and is clinically administered by intravenous injection. As intravenous chemotherapy intensifies the side effects experienced by OSCC patients, an alternative treatment option is desirable, particularly for older patients with OSCC who present with systemic disease complications. Generally, local injections of antitumor agents enhance tumoricidal activity and decrease side effects. However, the antitumor effects of peritumoral bevacizumab injections in OSCC are not fully understood. Therefore, the present study examined the effects of peritumoral bevacizumab injections in an experimental nude mouse model of OSCC through immunohistochemical staining for cluster of differentiation (CD)31 and α-smooth muscle actin (α‑SMA) and apoptosis assays. It was identified that peritumoral injections of bevacizumab significantly inhibited tumor growth in OSCC xenografts compared with peritumoral saline injections or no treatment (controls), and it was also revealed that treatment with bevacizumab significantly reduced CD31- and α-SMA-positive microvessel density (P<0.01) and increased level of tumor cell apoptosis (P<0.01) compared with the controls. In conclusion, these results collectively support the experimental basis for the clinical development of peritumoral bevacizumab injections for the treatment of OSCC.

UR - http://www.scopus.com/inward/record.url?scp=85046467274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046467274&partnerID=8YFLogxK

U2 - 10.3892/ol.2018.8399

DO - 10.3892/ol.2018.8399

M3 - Article

VL - 15

SP - 8627

EP - 8634

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 6

ER -